Vitamin D3 and analogs thereof for treating alopecia

A pharmaceutical composition comprising a vitamin D compound and a carrier, wherein the carrier consists of propylene glycol, ethanol and ethoxydiglycol or 2-(2-ethoxyethoxy)ethanol;

• wherein propylene glycol is present at about 30% (w/w), ethanol is present at about 60% (w/w), and ethoxydiglycol or 2-(2-ethoxyethoxy)ethanol is present at about 10% (w/w);
• and wherein the vitamin D compound is represented by Formula (I):
• wherein
• a and b are each independently a single or double bond;
• X is —CH2 when a is a double bond, or X is hydrogen or a hydroxyl substituted alkyl when a is a single bond;
• R1 is hydrogen, hydroxyl, alkoxyl, tri-alkyl silyl or alkyl, optionally substituted with one to three halogen, hydroxyl, cyano or —NR′R″ moieties;
• R2 is hydrogen, hydroxyl, —O-trialkyl silyl, or alkyl, alkoxyl or alkenyl, optionally substituted with one to three halogen, hydroxyl, cyano or —NR′R″ moieties;
• R3 is absent when b is a double bond or R3 is hydrogen, hydroxyl or alkyl, or R3 and R1 together with the carbon atoms to which they are attached may be linked to form 5-7 membered carbocyclic ring when b is a single bond;
• R4 is absent when b is a double bond or hydrogen, halogen or hydroxyl when b is a single bond;
• R5 is absent when a is a double bond or R5 is hydrogen, halogen or hydroxyl when a is a single bond;
• R6 is alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclicyl, alkyl-O-alkyl, alkyl-CO2-alkyl optionally substituted with one to five, hydroxyl, oxo, halogen, alkoxyl, aryl, heteroaryl, cyano, nitro or —NR′R″ moieties;
• R7 is alkyl optionally substituted with one to three hydroxyl, halogen, alkoxyl, aryl, heteroaryl, cyano, nitro or —NR′R″ moieties;
• R′ and R″ are each, independently, hydrogen, hydroxyl, halogen, alkyl or alkoxyl;
• the alkyl group is a fully saturated branched or unbranched having 1 to 20 carbon atoms;
• the alkoxy group has 1-7 carbon atoms;
• the alkenyl group is selected from the group consisting of vinyl, prop-1-enyl, allyl, butenyl, isopropenyl and isobutenyl;
• the alkynyl group is selected from the group consisting of ethynyl, prop-1-ynyl (propargyl), butynyl, isopropynyl and isobutynyl;
• the cycloalkyl group is a saturated or an unsaturated monocyclic, bicyclic, or tricyclic hydrocarbon group of 3-12 carbon atoms;
• the aryl group is a monocyclic or bicyclic aromatic hydrocarbon group having 6-20 carbon atoms in the ring portion;
• the heteroaryl group is a monocyclic or bicyclic aryl group, containing from 5-10 ring members selected from carbon atoms and 1 to 5 heteroatoms selected from O, N or S;
• and
• the heterocyclyl is a 4-, 5-, 6-, or 7-membered monocyclic, 7-, 8-, 9-, 10-, 11-, or 12-membered bicyclic or 10-, 11-, 12-, 13-, 14- or 15-membered tricyclic ring system, in which contains at least one heteroatom selected from O, S and N, where the N and S can also optionally be oxidized to various oxidation states, and pharmaceutically acceptable salts thereof.

A pharmaceutical composition comprising 1,25-dihydroxyvitamin D3 and a carrier, wherein the carrier consists of propylene glycol and ethanol at a % (w/w) ratio of propylene glycol to ethanol selected from the group consisting of 35:65;

• 36:64;
• 37:63;
• 38:62;
• 39:61;
• 40:60;
• 41:59;
• 42:58;
• 43:57;
• 44:56;
• and 45:55, wherein the pharmaceutical composition comprises 3-100 μg/mL of 1,25-dihydroxyvitamin D3.